MO HB2562

Requires sponsors and investigators of placebo-controlled clinical drug trials for terminal illnesses in Missouri to notify the Department of Health and Senior Services of their intent to conduct trials, including which drugs are being investigated

Creates a voluntary database within the cancer information reporting system where oncologists and health care providers can register their off-label drug usage practices for treating terminally ill patients

Mandates that trial sponsors provide prospective participants with a list of providers offering off-label drug treatments for similar medical conditions as part of informed consent proceedings under 21 CFR 50.25

Imposes a $50,000 fine on sponsors who willfully fail to obtain proper informed consent as required by the new provisions

Defines "terminally ill" as a medical state with no adequate treatment that will result in death in the near future, or permanent unconsciousness from which recovery is unlikely